RELX-TECHNOLOGY
17.9.2020 12:32:13 CEST | Business Wire | Press release
RELX Technology today announced the company has started operations at its newly-established e-cigarette bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005346/en/
The bioscience laboratory, located in International Bioindustry Valley, Shenzhen is currently conducting research on the impact of RELX products on animal cardiovascular, respiratory, and nervous systems, in order to better carry out a comprehensive impact evaluation of vapor products.
“Science is the foundation of trust. As the industry leader, we have the responsibility to expand the borders of e-cigarette science and explore the unknown,” said Kate Wang, founder and CEO of RELX.
At the RELX Lab Open Day, RELX also announced its plan to establish a “1+4” scientific research approach—i.e. anchored by Platform Development, followed by Toxicological Assessment, Clinical Assessment, Perception Behavior Study and Long Term Assessment.
According to Public Health England, e-cigarettes are 95% less harmful to health than smoking and have the potential to help smokers quit smoking. Many consumers have recognized e-cigarettes as a better alternative to traditional combustible cigarettes.
There are still many areas that require further long-term research, such as the actual harm reduction elements of e-cigarettes, the maximization of their harm reduction, and other potential effects of vaping.
“E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge,” said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, “The RELX bioscience lab’s mission is to explore the unknown. We want to collect evidence through a scientific approach and strive to prove the potential for e-cigarettes to be less harmful, and in doing so, provide users the option to choose an alternative.
To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018. The laboratory is certified by the internationally recognized China National Accreditation Service for Conformity Assessment. RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.
“The toxicological and pharmacological studies focus on the effects of RELX’s products,” said Xingtao Jiang, Head of RELX Lab, “For example, does it affect DNA or chromosomes, and what are the ingredients’ long-term impact on body organs and tissues? There is still a lot of research to be done.”
Xingtao Jiang also announced five preliminary findings from RELX’s research so far. Among these were that according to the data, the levels of harmful substances such as benzene and four TSNAs (Tobacco-specific N-nitrosoamines) emitted by RELX products are lower than those found in combustible cigarette smoke by over 99.1 percent and 99.8 percent respectively.
RELX is currently conducting research projects on different topics with six universities including the Sun Yat-sen University and Shenzhen Institutes of Advanced Technology, the Chinese Academy of Sciences, two hospitals and nine scientific research institutions.
ABOUT RELX Technology
Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.
Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 15:36:00 CEST | Press release
David Ogg appointed Vice Chairman and Brian Andreyko named CEO MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going o
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 15:00:00 CEST | Press release
The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction TransactionsDebt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
